U.S. pharma giant copyright scrapped two experimental weight loss products last calendar year—a as soon as-day by day tablet, lotiglipron, resulting from elevated liver enzymes plus a 2 times-day-to-day pill, danuglipron, as a result of potent side effects—but CEO Albert Bourla has explained the company is decided to “play and get” in the o